Posted by Michael Wonder on 29 Sep 2021
TransMedics receives FDA approval for its OCS Liver System for preservation and assessment of donor livers for transplantation
29 September 2021 - TransMedics today announced that the U.S. FDA has granted pre-market approval of its OCS Liver System for use with organs from donors after brain death and after circulatory death.
The OCS Liver System is indicated for the preservation and monitoring of haemodynamics and metabolic function which allows for ex-vivo assessment of liver allografts from brain death and circulatory death donor livers.
